Friday, 16 October 2026European Markets

CUMULEX Stock Falls By 18% In The Last 5 Sessions

Loading stream...

Cumulex (BEL 20: CLEX.BR) recently experienced a significant decrease in its shares this week, marking five consecutive sessions of decline. This trend also parallels with an overall market downtrend as reflected in the falling BEL 20 index. Cumulex's shares fell by 18.58%, from EUR2.26 down to a low of EUR1.84 as reported at 17:07 EST Wednesday, while the BEL 20 index has seen a decrease of 0.76% to EUR3,786.29.

History and Operations of Cumulex N.V.

Originally named Sucrerie et Raffinerie de l'Afrique Centrale NV, Cumulex N.V. started as a sugar plantation business in the Democratic Republic of Congo. Despite the significant change in name and business direction in March 2021, their current operations appear insufficient to validate such a change. Currently situated in Diegem, Belgium, Cumulex operates under the umbrella of Value8 NV's company.

Cumulex's Earnings Per Share (EPS)

Cumulex reported an earnings per share (EPS) figure of EUR-0.21, indicating that it is not generating profits. This performance has contributed to the decrease in its stock prices. Stocks with negative EPS figures for extended periods can often signal unstable or unsustainable business models, thus investors need to approach with caution.

Performance Analysis of Cumulex

Overall, over the past year, Cumulex shares have seen a significant decrease as its operations have struggled to demonstrate success, and profit has declined. Their lack of an identifiable operating plan adds to the uncertainty regarding its future in the stock market. Therefore, investors and potential shareholders need to consider these factors carefully when making financial decisions related to Cumulex.

More news about CUMULEX (CLEX.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com